Boundless Bio (BOLD) vs Connect Biopharma (CNTB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Boundless Bio (BOLD) has outperformed Connect Biopharma (CNTB) over the past year, gaining 114.6% versus a loss of 46.9%. Boundless Bio is the larger company by market cap ($60.1 million vs $59.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BOLD | CNTB |
|---|---|---|
| Share price | $2.64 | $0.9447 |
| Market cap | $60.05M | $59.49M |
| 1-day change | +2.72% | +4.34% |
| YTD return | +120.00% | -66.50% |
| 1-year return | +114.63% | -46.93% |
| 5-year return | — | -94.50% |
| EPS (TTM) | $-2.85 | $-1.19 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.16 | $3.82 |
| 52-week low | $0.961 | $0.85 |
| Distance from 52-week high | -16.56% | -75.27% |
| Average volume | 180.13K | 3.82M |
| Shares outstanding | 22.75M | 62.97M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BOLD has outperformed CNTB by 161.6 percentage points over the past year.
BOLD vs CNTB FAQ
Which is bigger, Boundless Bio or Connect Biopharma?
Boundless Bio (BOLD) is larger, with a market capitalization of $60.05M compared with $59.49M for Connect Biopharma (CNTB).
Which stock has performed better over the past year, BOLD or CNTB?
BOLD returned +114.63% over the past 12 months, compared with -46.93% for CNTB (price return, excluding dividends). Past performance does not predict future results.
Are Boundless Bio and Connect Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.